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Abstract Raf kinase inhibitor protein (RKIP) was originally identified as a protein that bound membrane
phospholipids and was named phosphatidylethanolamine binding protein-2 (PEBP-2). RKIP was than identified as a
protein that bound Raf and blocked its ability to phosphorylate MEK, thus earning its new name of RKIP. Subsequent to
identification of its role in the Raf:MEK pathway, RKIP has been demonstrated to regulate several other signaling pathways
includingG-protein signaling andNF-kB signaling. Its involvement in several signaling pathways has engendered RKIP to
contribute to several physiological processes including membrane biosynthesis, spermatogenesis, neural development,
andapoptosis. RKIP is expressed inmany tissues includingbrain, lung, and liver and thus, dysregulationof RKIP expression
or function has potential to contribute to pathophysiology in these tissues. Loss of RKIP expression in prostate cancer cells
confers a metastatic phenotype on them. Additionally, restoration of RKIP expression in a metastatic prostate cancer cell
line does not effect primary tumor growth, but it does inhibit prostate cancermetastasis. These parameters identify RKIP as
a metastasis suppressor gene. In this review, the biology and pathophysiology of RKIP is described. J. Cell. Biochem. 94:
273–278, 2005.  2004 Wiley-Liss, Inc.
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Raf kinase inhibitor protein (RKIP) is a
member of the phosphatidylethanolamine bind-
ing protein (PEBP) family. The RKIP family of
proteins is highly conserved and does not share
significanthomologywith other protein families
[Banfield et al., 1998]. RKIP is a small, cytosolic
protein originally purified from bovine brain
and identified to bind phospholipids [Yeung
et al., 1999; Vallee et al., 2001; Simister et al.,
2002]. RKIP was initially identified as human
PEBPwhere it was shown to have a role in lipid
metabolism and phospholipid membrane bio-
genesis. Recent investigations have identified
that RKIP inhibits Raf-mediated activation of
MEK, which accounts for it current name.
Aberrant RKIP activity is associated with an
increasing number of diseases via its associa-
tionwith signal transduction pathways [Mitake
et al., 1995, 1996; Banfield et al., 1998; Tsugu
et al., 1998; Yeung et al., 1999;Maki et al., 2002;
Simister et al., 2002; Corbit et al., 2003]. In this
review, the biology and pathophysiology of
RKIP is described.
LOCALIZATION OF RKIP
Immunohistochemical analysis of RKIP
expression reveals that it is often found present
in the cytoplasm and at the plasma membrane
in many different tissues [Simister et al., 2002].
RKIP expression is found in a variety of neural
cells including brain oligodendricytes, Schwann
cells, Purkinje cells of the cerebellum, and
within cortical and hippocampal layers of the
brain [Katada et al., 1996, 2000; Moore et al.,
1996; Taiji et al., 1996; Frayne et al., 1998,
1999]. In addition, RKIP is expressed in a large
number of non-neural tissues including sper-
matids, Leydig cells, andepididymal epithelium
of the testis; steroidogenic cells of the adrenal
gland zona fasciculata; proximal kidney tubule
epithelium; enterocytes, goblet cells, and
plasma cells of the small intestine; plasma
cells of the lymph node; plasma cells; and
megakaryocytes of the spleen; heart; liver; and
 2004 Wiley-Liss, Inc.
Grant sponsor: National Cancer Institute; Grant number:
CA098513.
*Correspondence to: Evan T. Keller, DVM, PhD, Room 5304
CCGCB, 1500 E. Medical Center Dr., University of
Michigan, Ann Arbor, MI 48109-0940.
E-mail: etkeller@umich.edu
Received 22 April 2004; Accepted 23 April 2004
DOI 10.1002/jcb.20169
epididymis, lung bronchioles, mesenteric
lymph node, oviduct, ovary, lactating mam-
mary glands, uterus, prostate epithelium, and
thyroid [Frayne et al., 1998; Fu et al., 2003].
Although it is found in many secretory organs,
RKIP is not found extracellular fluids such as
blood, saliva, milk, uterine fluid, parotid fluid,
prostate secretions, or seminal vesicle secre-
tions [Schoentgen and Jolles, 1995].
RKIP FUNCTION
The wide distribution of RKIP in many
different tissues suggests that it plays a role in
a multitude of different physiological processes
(Fig. 1). In neural tissues, RKIP was found to
enhance in vitro acetylcholine synthesis by
upregulating choline acetyltransferase and
possibly stimulating cholinergic neuronal path-
ways in rat medial septal nuclei [Mitake et al.,
1995; Ojika et al., 1995; Taiji et al., 1996;
Tohdoh et al., 1997].
RKIP also has several functions in gonadal
tissues. For example, rat epididymal secretions
and sperm plasmamembranes contain proteins
with sequences similar to bovine brain RKIP
[Jones and Hall, 1991]. Furthermore, RKIP
released from spermatozoa may be involved
with membrane biogenesis and maintenance of
antigen segregation in spermatozoa [Perry
et al., 1994]. Studies in the rat testis show that
RKIP proteins may be involved in organization
of the seminiferous epithelium or the transfer of
phosphatidylethanolamine to other germ cells
[Saunders et al., 1995]. Due to its presence in
Leydig cells, Frayne et al. [1999] suggested a
role for RKIP as a lipid carrier or binding
protein within the rat testis that contributes to
membrane organization during spermatogen-
esis.
RKIP AND INTRACELLULAR SIGNALING
RKIP modulates a variety of different signal
pathways (Fig. 2). The role of RKIP in cell
signaling was identified in a yeast two-hybrid
assay for screening clones from a human T-cell
library that bound to Raf-1 kinase binding
domains [Yeung et al., 1999]. RKIP was shown
to bind Raf-1, MEK-1, and weakly bind to ERK-
2, interfering with MEK phosphorylation and
activation by Raf-1. However, RKIP was not a
substrate for Raf-1 or MEK. RKIP did not bind
to Ras, nor possess kinase activity. It appears
that RKIP acts to set the threshold for Raf-1
activation and subsequent activation of the
MEK/ERK pathway. Raf-1 dissociates from its
complexwithMEKin thepresence ofRKIP.Asa
result, downstream mitogen-activated protein
kinase (MAPK) signaling is interrupted and
diminished. As stated earlier, RKIP can bind to
Raf-1 or MEK, yet not at the same time, and
binding to either one is enough to cause down-
stream inhibition [Yeung et al., 2000]. In
addition, it was postulated that RKIP may be
involved in growth, transformation, and differ-
entiation [Yeung et al., 1999] as these pathways
are often deregulated in cancer.
RKIP interacts with small GTP-binding pro-
teins, yet not GTP itself [Bucquoy et al., 1994]
and can be purified alongwith m opioid receptors
via morphine affinity chromatography using
tissue derived from rat brain [Grandy et al.,
1990]. Grandy et al. [1990] speculated that
RKIP was a membrane-associated protein,
which may alter opioid binding via an enzy-
matic- or structural-induced reaction. Using
hydrophobic cluster analysis and molecular
modeling, Schoentgen et al. [1992] showed that
the bovine RKIP may possess a potential
nucleotide binding site and suggested that it
belongs to the kinase family and promote the
transfer of hydrophobic ligands to the plasma
membrane. Co-expression of human RKIP with
human opioid or somatastatin receptors (G-
protein-coupled receptors) in Xenopus laevis
oocytes provided in vivo evidence that RKIP
could modulate G-protein-coupled signaling
[Kroslak et al., 2001].
Fig. 1. Physiological roles of RKIP. RKIP has multiple functions
in organs such as the heart and brain and at the cellular level as
indicated. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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Protein kinase C (PKC), which phosphory-
lates target proteins that control growth,
differentiation, and transcription, can inacti-
vate RKIP through phosphorylation of RKIP on
serine 153 and alleviate its inhibition of Raf-1
[Corbit et al., 2003]. PKC is normally recruited
to the plasma membrane and activated by
diacylglycerol. Its location near the plasma
membrane may place it in close proximity to
RKIP, which also binds to phospholipids [Bazzi
et al., 1992]. As a result, PKC along with RKIP,
function as unique selective regulators of the
Raf-1/MEK/ERK growth factor signaling cas-
cade. When RKIP is phosphorylated, it releases
fromRaf-1 and can bind onto G-protein-coupled
receptor kinase-2 (GRK-2) preventing GRK-2’s
ability to inhibit G-protein-coupled receptor
activity [Lorenz et al., 2003].
In summary, RKIP impacts multiple signal-
ing pathways and RKIP activity itself is regu-
lated by PKC. Due to its involvement in several
signaling pathways, RKIP modulates cellular
functions that are dependent or altered by these
signaling pathways.
RKIP AS A SUPPRESSOR OF METASTASIS
Metastasis, defined as the formation of pro-
gressively growing secondary tumor foci at sites
discontinuous from the primary lesion [Yoshida
et al., 2000], is a multi-step metastatic process.
Initially, a metastatic cancer cell escapes from
the primary tumor, enters the circulation,
invades a distant tissue site and grows into a
macroscopic tumor at the target site. Since
many steps are required formetastasis to occur,
it may be possible to block metastasis by
inhibiting a single protein that is required for
the completion of any one of these steps [Welch
and Rinker-Schaeffer, 1999]. This hypothesis
has given rise to the concept of metastasis
suppressor genes (MSG). In brief, MSGs are
defined as genes that inhibit the metastatic
process, but not primary tumorigenesis. Several
Fig. 2. Role of RKIP in intracellular signaling.Upper panels: In
the inactive state, RKIP is unphosphorylated and binds to
activated Raf, inhibiting its ability to activate MEK. Additionally,
RKIP binds to several proteins that induce NF-kB activity
including transforming growth factor b-activated kinase-1
(TAK), I-kB kinase a (IKKa), I-kB kinase b (IKKb), and NF-kB-
inducing kinase (NIK). Also, G-protein-coupled receptor kinase-
2 (GRK-2) binds to G-protein-coupled receptor (GPCR) resulting
in inhibition of its activity. Lower panel: Activation of protein
kinase C (PKC) results in phosphorylation of RKIP. The
phosphorylatedRKIP releasesRaf,whichcan thenphosphorylate
MEK, which in turns phosphorylates ERK. The phosphorylated
RKIP can then bind to GRK-2, causing it to release, which allows
GPCR to phosphorylate its downstream targets, including
Raf. RKIP release from TAK, IKKa, IKKb, and NIK results in
phosphorylation and degradation of I-kB, which culiminates in
release of NF-kB that translocates to the nucleus and binds on to
target gene promoters. [Color figure can be viewed in the online
issue, which is available at www.interscience. wiley.com.]
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studies that have demonstrated that loss of
function of specific genes is an important event
in the progression to malignancy support the
concept of MSGs [Steeg et al., 1988; Dong et al.,
1996; Yang et al., 1997; Yoshida et al., 2000].
Due to their ability to regulate the metastatic
process, MSGs are potential diagnostic and
therapeutic targets. Accordingly, identification
of MSGs may lead to advances in prostate
cancer therapy.
RKIP has been identified to have the proper-
ties of aprostate cancerMSGthrough inhibiting
several potential pro-metastatic functions
(Fig. 3). The initial clue that RKIP plays a role
as a prostate cancerMSGwas thatRKIPmRNA
expression was decreased in a metastatic
prostate cancer cell line compared to its non-
metastatic parental cell line [Fu et al., 2002].
This relationship was confirmed at the protein
level using immunohistochemistry to compare
RKIP expression in non-neoplastic prostate
tissue, primary prostate cancer, and prostate
cancermetastases [Fu et al., 2003]. Specifically,
RKIP expression level was highest for benign
tissue, lower for cancerous tissue (declining
with increasing Gleason score), and not detect-
able in metastases (of several different sites).
These results provided strong evidence that loss
of RKIP is associated with the development of
prostate cancer metastases.
To examine the function of RKIP during
prostate cancer progression, RKIP expression
was modulated in prostate cancer cells to
determine the effect of different RKIP levels
on the prostate cancer cells metastatic ability.
Modulating RKIP expression had no effect on
the ability of the cells to grow in vitro or on their
ability to form colonies in soft agar. These
results suggest that RKIP has no effect on these
two primary tumorigenic properties of human
prostate cancer cells. However, increasing
RKIP expression in metastatic cancer cells
decreased in vitro invasive ability [Fu et al.,
2003].Conversely, decreasingRKIPexpression,
using antisense, in non-metastatic prostate
cancer cells increased their in vitro invasive
ability. These results suggest thatRKIP expres-
sion is inversely associated with the invasive-
ness of prostate cancer cells in vitro.
When the metastatic tumor cells that had
RKIP expression restored were injected ortho-
pically, the mice developed 70% lessmetastases
(to lung) then mice that received the metastatic
cells transfected with empty vector. Further-
more, in the mice that had received cells
expressing restored RKIP and that developed
metastases, the number of metastases was far
fewer than in the mice that had received the
cells expressing low levels of RKIP. Addition-
ally, there was less vascular formation and less
vascular invasion in the primary tumors
derived from the mice that received the cells
engineered to express RKIP. Taken together,
these results suggest that RKIP functions as a
suppressor of metastasis through decreasing
angiogenesis and vascular invasion.
In addition to anti-metastatic properties,
RKIP has pro-apoptotic properties in tumor
cells. Exposure of breast and prostate cancer
cells to chemotherapeutic agents induces RKIP
expression and apoptosis [Chatterjee et al.,
2004]. Small interfering RNA (siRNA) that
targets and reduces RKIP expression dimi-
nishes chemotherapeutic-induced apoptosis.
Additionally, breast and prostate cancer cells
that have low levels of RKIP expression are
resistant to chemotherapeutic-induced apopto-
sis [Chatterjee et al., 2004]. Restoration of RKIP
levels sensitizes the cells to apoptosis. Taken
together, these results suggest that loss of
RKIP, as occurs in prostate cancer, may confer
chemotherapeutic resistance on cancer cells
and overall enhance tumor progression.
CONCLUSIONS
Prior to being named RKIP, this protein had
been recognized as PEBP formany years. PEBP
had contributed to many different physiologic
Fig. 3. Potential role of RKIP in metastasis. RKIP maymodulate
a variety of cellular functions that can impact development of
successful metastases. For example, RKIP may inhibit angiogen-
esis and cell invasiveness and promote apoptosis. Thus, de-
creased RKIP expression promotes angiogenesis, cell invasion
and confers resistance to apoptosis. [Color figure can be viewed
in the online issue, which is available at www.interscience.
wiley.com.]
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activities including reproductionandneurophy-
siology. Recent research activity has identified
that RKIP regulates an important signaling
cascade, i.e., the Raf–MEK–ERK kinase cas-
cade. In addition to this role, RKIP also
modulates G-protein and NF-kB signaling.
RKIP has been shown to contribute to several
anti-cancer activities including induction of
apoptosis and inhibition of metastasis. As
prostate cancer progresses, it loses RKIP
expression, which in turn, promotes metastasis
and inhibition of apoptosis. These observations
suggest that restoring RKIP expression or
inhibiting effectors downstream of Raf that are
normally blocked byRKIPwill have potent anti-
cancer effects.
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